Skip to Content
Søg Menu

SABCS 2025: Favorable Benefit–Risk Profile of Sacituzumab Govitecan in Previously Untreated Metastatic TNBC PD-L1–ineligible Metastatic Triple-Negative Breast Cancer

New ASCENT-03 data highlight sacituzumab govitecan as an effective first-line option with a manageable safety profile for patients with metastatic triple-negative breast cancer who are ineligible for PD-L1–targeted therapy.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%

/ Jan Andreasen
NBCNBrystcancer
Kirsten Marie Woolpert

SABCS 2025: Patterns of Opioid Use Among Breast Cancer Survivors

/ Kirsten Marie Woolpert
NBCNSABCS25Brystcancer Play the Video 4:41
Sandra Jensen

Metastatic Deposit Size as a Predictor of Axillary Disease After Neoadjuvant Chemotherapy

/ Sandra Jensen
NBCNBrystcancer Play the Video 5:52
Peeter Karihtala

The Clinical Value of Immuno-Oncological Treatments in Early Breast Cancer

/ Peeter Karihtala
NBCNOnkologiapäivät 2025Brystcancer Play the Video 09:38

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
ESMO25NBCNBrystcancer Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
ESMO25NBCNBrystcancer Play the Video 05:53

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top